Screener
CG Oncology CGON Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 54,657 | 31,331 | 98,387 | 58,799 |
| General and administrative | 28,976 | 17,410 | 49,756 | 32,198 |
| Total operating costs and expenses | 87,558 | 48,741 | 155,030 | 90,997 |
| Loss from operations | (86,401) | (48,741) | (152,790) | (90,945) |
| Other income (expense), net | ||||
| Interest income, net | 7,329 | 7,319 | 13,617 | 15,066 |
| Other income (expense), net | 16 | (4) | (85) | 1 |
| Total other income, net | 7,345 | 7,315 | 13,532 | 15,067 |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's operating income?
- CG Oncology (CGON) reported operating income of -$86.4M in Q2 2026.
- How has CG Oncology's operating income changed year-over-year?
- CG Oncology's operating income decreased by 77.3% year-over-year, from -$48.74M to -$86.4M.
- What is the long-term trend for CG Oncology's operating income?
- Over 2 years (2023 to 2025), CG Oncology's operating income has grown at a 85.5% compound annual growth rate (CAGR), from -$55.45M to -$190.77M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about CG Oncology's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude